al’s pilot phase I/IIA study investigated the anti-CD19 CAR T-cell therapy Tisagenlecleucel in 30 children and adults with relapsed/refractory ALL (not Ph + specific) and found a CR rate of 90%, with 19 patients having sustained remissions (follow-up period of 2–24 months) [67]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.